In vitro diagnostics (IVD) is a method used for detection and identification of diseases in an artificial environment using samples such as blood, urine, stool, tissues and other body fluids, which are derived from the human body. IVD includes several techniques such as immunodiagnostic, infectious diseases testing, blood testing, clinical chemistry, molecular diagnosis and other such techniques. Considerable increase in the number of chronic and infectious diseases, growing awareness towards healthcare solutions and technological advancements in healthcare industry encouraged doctors and researchers to shift their focus from traditional diagnostic methods to personalized medicines.
The overall revenue of the Asia Pacific IVD market accounted for about $12.9 billion in 2015, and is estimated to reach $19.0 billion by 2022, registering a CAGR of 5.6% over the forecast period. The increased application of personalized medicines and widespread knowledge of rare diseases are boosting the growth of Asia Pacific IVD market. Moreover, growing need of IVD testing owing to increasing incidences of chronic and infectious diseases and growing geriatric population prone to immunological disorders drives the market growth. The Asia Pacific IVD market has evolved over the years with the launch of several innovative techniques used across multiple therapeutic areas. However, stringent regulatory policies and reimbursements issues in few countries limit the growth of this market. The rising demand for technologically advanced diagnostic devices, rise in GDP and per capita income and rise in disposable incomes facilitate a huge potential for the Asia Pacific IVD market in the Asia-Pacific region. Similarly, the development of a new range of condition-specific markers and tests along with the advancement in genomics and proteomics are creating new opportunities in emerging economies.
The Asia-Pacific IVD market is segmented based on product type, technique, indications, end user and country. Based on technique, the market is segmented into immunodiagnostics, blood testing, molecular diagnostics, tissue diagnostics, clinical chemistry and other clinical technique. Immunodiagnostic is the highest revenue-generating segment in the overall IVD techniques market. However, the blood testing is the fastest growing technique in the overall IVD techniques market due to its ability to accurately detect the primary cause of the disease.
Based on product type, the market is segmented into instruments, reagents, services & software. Reagents held the highest market share in the Asia Pacific IVD market followed by rapidly growing instrument segment. Reagents are largely used in various equipment and play a key role in the overall diagnosis process. The application segment is categorized into infectious diseases, cancer, cardiac diseases, immune system diseases, nephrological diseases, gastrointestinal diseases, and others. Infectious diseases segment was the highest revenue-generating segment in 2015 and would continue to maintain its position throughout the forecast period, due to the rise in incidences of infectious diseases such as HIV/AIDS, Chlamydia and Hepatitis.
Hospitals and laboratories, academics & medical schools, point-of-care testing and others form the end users segment in the Asia-Pacific IVD market. Stand-alone laboratories generate the highest revenue, followed by hospitals. A significant rise in the number of hospitals and laboratories across the Asia-Pacific region along with increased awareness about developments in healthcare largely contribute to the growth of these segment.
Based on country, the Asia-Pacific IVD market is segmented into India, China, Japan, Australia, and other Asia-Pacific countries. Japan held the dominant share, around 35.3% in 2015 in the Asia-Pacific IVD market, owing to the high demand for testing in outpatient clinics, huge population base and rising medical insurance services by the Japan government. Moreover, China and Australia hold the significant market share due to the well-supported reimbursement facilities and well-regulated IVD devices, which comes under the regulation of medical devices. However, India registers highest CAGR i.e. 7.1% during the forecast period.
Product launch was the key strategy adopted by market payers, owing to the dynamic nature of the market in terms of technology advancement. The leading companies profiled in this report are, Danaher Corporation, Vela Diagnostics, Siemens AG, Affymetrix, Alere Inc., BioMerieux, Roche Diagnostics, Bio-Rad Laboratories, Becton, Dickinson And Company, Abbott Laboratories Inc., Arkray Inc., Sysmex Corporation, Johnson & Johnson, Siemens Healthcare and Trans Asia BioMedicals Ltd.
KEY BENEFITS FOR STAKEHOLDERS:
APAC IVD MARKET KEY SEGMENTS:
By Product type
SIMILAR MARKET STUDIES
Blood Market by Product [Whole Blood Collection (System and Reagents), Source Plasma Collections (System and Reagents) Blood Therapeutics (IVIG, Albumin, Hyperimmune, Factor VIII, Factor IX, and Others), Blood Typing Products (System and Reagents), Blood Screening (Systems and Reagents), Blood Processing Equipment & Associated Products (System and Reagents)] and End User (Blood & Blood Component Bank, Diagnostic Laboratories, Ambulatory Surgical Centers, Hospitals, and Others): Global Opportunity Analysis and Industry Forecast, 2017-2023
Blood is a major necessity for patients suffering from injuries and viral infections, which require blood transfusion. The patients are either given whole blood or blood components for quick recovery and healing, resulting into increased demand for blood banks.
July 2017 | $5370 | View Details >>
The global Vernier Caliper market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Japan plays an important role in global market, with market size of xx million ...
July 2017 | $3085 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research